We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+4.49%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$9.36B
AUM Growth
-$287M
Cap. Flow
-$74.9M
Cap. Flow %
-0.8%
Top 10 Hldgs %
76.51%
Holding
102
New
8
Increased
20
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$42.6M
2
BCYC
Bicycle Therapeutics
BCYC
+$31.8M
3
GRAL
GRAIL Inc
GRAL
+$26.5M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$22M
5
RVMD icon
Revolution Medicines
RVMD
+$18.6M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$212M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$17.4M
3
TNGX icon
Tango Therapeutics
TNGX
+$5.78M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$5.31M
5
BMEA icon
Biomea Fusion
BMEA
+$5.24M

Sector Composition

Rank Sector Weight
1 Healthcare 98.66%
2 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALGS icon
76
Aligos Therapeutics
ALGS
$41.7M
$3.31M 0.04%
83,055
– –
PRME icon
77
Prime Medicine
PRME
$615M
$3M 0.03%
1,028,466
– –
TARA icon
78
Protara Therapeutics
TARA
$228M
$2.83M 0.03%
536,832
– –
ELVN icon
79
Enliven Therapeutics
ELVN
$4.38B
$2.58M 0.03%
114,833
– –
ARCT icon
80
Arcturus Therapeutics
ARCT
$382M
$2.57M 0.03%
151,329
– –
CMPX icon
81
Compass Therapeutics
CMPX
$432M
$2.26M 0.02%
1,557,630
– –
GBIO
82
DELISTED
Generation Bio
GBIO
$2.06M 0.02%
194,495
– –
HOOK
83
DELISTED
HOOKIPA Pharma
HOOK
$1.63M 0.02%
812,814
– –
MRSN
84
DELISTED
Mersana Therapeutics
MRSN
$1.55M 0.02%
43,445
– –
VTVT icon
85
vTv Therapeutics
VTVT
$132M
$1.34M 0.01%
97,314
– –
RCKT icon
86
Rocket Pharmaceuticals
RCKT
$385M
$1.22M 0.01%
+97,079
New +$1.46M
PTCT icon
87
PTC Therapeutics
PTCT
$5.83B
$921K 0.01%
+20,400
New +$873K
IPSC icon
88
Century Therapeutics
IPSC
$375M
$805K 0.01%
797,460
– –
PMVP icon
89
PMV Pharmaceuticals
PMVP
$71.1M
$486K 0.01%
322,024
– –
ACRV icon
90
Acrivon Therapeutics
ACRV
$94.7M
$318K ﹤0.01%
52,885
– –
FHTX icon
91
Foghorn Therapeutics
FHTX
$420M
$213K ﹤0.01%
45,027
– –
TYRA icon
92
Tyra Biosciences
TYRA
$1.55B
$147K ﹤0.01%
10,607
– –
SRZNW
93
DELISTED
Surrozen Inc Warrant
SRZNW
$17.8K ﹤0.01%
833,333
– –
ALEC icon
94
Alector
ALEC
$264M
– –
-927,264
Closed -$4.32M
JBIO
95
Jade Biosciences
JBIO
$1.36B
– –
-17,970
Closed -$1.31M
BCRX icon
96
BioCryst Pharmaceuticals
BCRX
$2.44B
– –
-75,778
Closed -$576K
CRNX icon
97
Crinetics Pharmaceuticals
CRNX
$8.99B
– –
-103,927
Closed -$5.31M
NAMS icon
98
NewAmsterdam Pharma
NAMS
$3.33B
– –
-96,711
Closed -$1.61M
PFE icon
99
Pfizer
PFE
$160B
– –
-35,000
Closed -$1.01M
TNGX icon
100
Tango Therapeutics
TNGX
$4.03B
– –
-750,000
Closed -$5.78M
1 2 3
4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2024 Portfolio in Review

As of Q4 2024, Julian Baker held 102 positions worth $9.36B, down 3% from $9.65B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Julian Baker's Q4 2024 filing shows 8 new, 20 increased, 5 reduced and 7 closed positions. Its largest new stake was GRAIL Inc: 1,630,125 shares worth $29.1M. The largest sale was BeOne Medicines Ltd, an estimated $212M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q4 2024 buy was GRAIL Inc: 1,630,125 shares worth $29.1M.
  • Julian Baker added most to Insmed in Q4 2024, an estimated $42.6M increase.
  • Julian Baker's biggest Q4 2024 reduction was BeOne Medicines Ltd, cutting an estimated $212M.
  • Julian Baker fully exited Tango Therapeutics in Q4 2024, selling an estimated $5.78M.
  • Julian Baker's ten largest holdings make up 77% of its $9.36B portfolio in Q4 2024.
  • Julian Baker opened 8 new positions and closed 7 in Q4 2024.
  • Julian Baker's portfolio value fell 3% quarter-over-quarter to $9.36B.

Based on Baker Bros. Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.